Site icon TBi-Sektionen

Exjobb hos Affibody – vår 2026

Sök ett spännande exjobb hos Affibody. Läs mer om projektet och hur man söker HÄR!

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod® half-life extension technology.
In the research operations department, we develop and characterize new Affibody® molecules. The ones with the most interesting properties are then selected as CD (Candidate Drug). In the spring of 2026, we are planning a 30 credits degree project with the preliminary title:
Development of fluorescence labeled HSA assays for
visualization of cell-binding Affibody® molecules
Background
Affibody AB runs several early discovery projects aimed at identifying novel, clinically
relevant Affibody® molecules. Candidate molecules are subjected to a broad spectrum of
in vitro pharmacology studies to characterize their activity. A key aspect to support Affibody’s innovative radiopharmaceutical pipeline is to identify Affibody® molecules with
strong and specific binding to cellular receptor targets.
Execution
Cell binding assays are commonly used to identify molecules that can bind to tumor cell
targets. If the targeting molecule is a monoclonal antibody there are several commercially
available reagents for detection of bound antibodies. With Affibody® molecules an extra
staining step with proprietary antibody reagents are currently needed. The project aims to
develop an alternative way of visualizing cell-bound Affibody® molecules by utilizing
the strong interaction between the albumin-binding domain (ABD), often fused to Affibody® molecules for half-life extension, and human serum albumin (HSA).
Key features included in the project:

Exit mobile version